To our knowledge, CYP2B6 expression in NAFLD and NASH patients based on gender has yet to be determined; however, it is established that premenopausal women are protected from dysmetabolism, and NAFLD more often affects men [72]. Here, CYP2B6 is linked to metabolic dysfunction-associated steatohepatitis.